| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/424455 |
| P698 | PubMed publication ID | 15486857 |
| P2093 | author name string | John Wong | |
| Robert S Wallis | |||
| Michael Broder | |||
| David Beenhouwer | |||
| P433 | issue | 8 | |
| P304 | page(s) | 1254-1255 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Granulomatous infections due to tumor necrosis factor blockade: correction | |
| P478 | volume | 39 |
| Q30248908 | A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis |
| Q38661516 | Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. |
| Q45397328 | Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis |
| Q34466861 | Advancing host-directed therapy for tuberculosis |
| Q34135558 | Averting inflammation by targeting the cytokine environment |
| Q46143952 | Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q36705704 | Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor |
| Q34081925 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). |
| Q28481571 | Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung |
| Q30009390 | Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss |
| Q36911254 | High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy |
| Q38518485 | Host susceptibility to non-tuberculous mycobacterial infections |
| Q35585867 | How do register data support clinical decision-making? |
| Q34545296 | Human granuloma in vitro model, for TB dormancy and resuscitation |
| Q36292624 | Immunological control of tuberculosis: role of tumour necrosis factor and more |
| Q37358271 | Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature |
| Q33371653 | Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study |
| Q35605635 | Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists |
| Q84594220 | Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease? |
| Q34297816 | Latent tuberculosis infection: myths, models, and molecular mechanisms |
| Q84229705 | Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent |
| Q38848891 | Mathematical Models of Tuberculosis Reactivation and Relapse |
| Q35099713 | Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity |
| Q84784155 | New immunosuppressive agents and risk for invasive fungal infections |
| Q35692257 | Nocardia infections among immunomodulated inflammatory bowel disease patients: A review. |
| Q33836681 | Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy |
| Q27319559 | Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model |
| Q36086911 | Polarized response of endothelial cells to invasion by Aspergillus fumigatus |
| Q36981540 | Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis |
| Q43190407 | Preventing tuberculosis in children receiving anti-TNF treatment |
| Q54920016 | Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation. |
| Q33939033 | Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review |
| Q40425780 | Pulmonary Mycobacterium avium Infection in a Patient with Crohn's Disease under Azathioprine Treatment |
| Q38267397 | Pulmonary Mycobacterium kansasii Infection Mimicking Malignancy on the (18)F-FDG PET Scan in a Patient Receiving Etanercept: A Case Report and Literature Review. |
| Q36821981 | Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma |
| Q56966511 | Recomendações para o diagnóstico e tratamento das tuberculoses latente e activa nas doenças inflamatórias articulares candidatas a terapêutica com fármacos inibidores do factor de necrose tumoral alfa. Revisão de Março de 2008**O presente ar |
| Q36639862 | Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor |
| Q34065405 | Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry |
| Q33667789 | Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia |
| Q92819877 | Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis |
| Q43490943 | Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine |
| Q36257295 | Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors |
| Q33777367 | The immunology of tuberculosis: from bench to bedside |
| Q35919214 | The safety of etanercept for the treatment of plaque psoriasis. |
| Q36968737 | Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis |
| Q93047779 | Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into Mycobacterium tuberculosis Infection |
| Q37298854 | Tumour necrosis factor antagonists: structure, function, and tuberculosis risks |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q79978249 | Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept |
| Q84279863 | [Etanercept and infection - latent tuberculosis] |
| Q81786240 | [Interdisciplinary point of contact between rheumatology and pneumology] |
| Q52937753 | [Rheumatology]. |
| Q53513741 | [Tuberculosis during treatment by TNFalpha-inhibitors]. |
Search more.